Early Diagnosis Of Childhood Cerebral ALD

Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy

NCT02948062•Masonic Cancer Center, University of Minnesota

Summary

The goal of this single institution study is to evaluate boys with adrenoleukodystrophy (ALD) diagnosed early in life, and to prospectively monitor them to determine parameters that will facilitate earlier detection of the childhood cerebral form of the disease. These at-risk subjects will be assessed yearly through travel to the University of Minnesota, where plasma and cerebral spinal fluid (CSF) biomarker studies, MRI based imaging and neuropsychological assessments will be performed at the University of Minnesota Masonic Children's Hospital and Clinics. The MRI and lumbar puncture to obtain CSF will be obtained under sedation. In addition, at intervening 6 months intervals information will be obtained remotely, including surveys and MRI's in their home location. Also at that time blood samples will be obtained locally and shipped to the University of Minnesota for study. There is no therapeutic intent in this study.

Eligibility

Age

1 - 5 years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Boys with confirmed adrenoleukodystrophy, as determined by very long chain fatty acid (VLCFA) analysis and/or genotyping. Genotyping is not necessary for diagnosis.
•Between 1 and 5 years of age, inclusive at the time of consent.
•Able to undergo a sedation
•English as primary language of the household, to maximize consistency of the neuropsychological/developmental testing.
•Voluntary written parental/guardian consent

Exclusion Criteria

•Evidence of cerebral disease at time of enrollment - patients over 3 years of age must have an MRI within 4 months of signing consent to confirm that there is no evidence of cerebral disease
•Inability or unwillingness to travel to the University of Minnesota once a year for the duration of the study
•Evidence of cerebral disease by standard T2/FLAIR MRI. If a subject develops cerebral ALD during the study, they will come off study, as it is anticipated that they would be considered for transplantation.

Locations (1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

Key Dates

Start Date

November 1, 2018

Primary Completion Date

July 1, 2023

Completion Date

July 1, 2023

Last Updated

July 6, 2018

Conditions

Adrenoleukodystrophy

The Myelin Disorders Biorepository Project

NCT03047369

LeukodystrophyWhite Matter Disease+64 more

View study

RECRUITINGPHASE1

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863

AdrenoleukodystrophyBatten Disease+10 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 6, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Early Diagnosis Of Childhood Cerebral ALD

Inclusion Criteria

Exclusion Criteria

The Myelin Disorders Biorepository Project

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

Adrenoleukodystrophy National Registry Study

Quality of Life in Women with X-linked Adrenoleukodystrophy

Precision Exercise in Children With Malignant Hemopathies

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product